XTL Biopharmaceuticals Ltd. (XTLB) 10-Year Financial Performance & Capital Metrics

XTLB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.Show more

Revenue $451K
EBITDA -$2M -158.2%
Net Income -$1M -57531.9%
EPS (Diluted) -0.60
Gross Margin 0.67%
EBITDA Margin -437.47%
Operating Margin -481.6%
Net Margin -227.72%
ROE -26.83% -46727.4%
ROIC -54.11% -28.5%
Debt/Equity 0.03
Interest Coverage -25.26 +86.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 29.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM42.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM45.45%

ROCE

10Y Avg-31.57%

5Y Avg-24.59%

3Y Avg-30.76%

Latest-50.73%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	451K
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	1K	1K	1K	0	448K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.99%
Gross Profit+	0	0	0	0	0	-1K	-1K	-1K	0	3K
Gross Margin %	-	-	-	-	-	-	-	-	-	0.01%
Gross Profit Growth %	1%	-	-	-	-	-	0%	0%	1%	-
Operating Expenses+	2M	1.71M	1.25M	793K	842K	948K	1.03M	880K	765K	2.17M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	4.82%
Selling, General & Admin	1.41M	1.26M	1.19M	755K	807K	910K	1M	850K	734K	2.05M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	4.54%
Research & Development	578K	443K	43K	38K	35K	38K	30K	30K	31K	98K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	0.22%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	31K
Operating Income+	-3.61M	-2.56M	-1.25M	-793K	-842K	-948K	-1.03M	-880K	-765K	-2.17M
Operating Margin %	-	-	-	-	-	-	-	-	-	-4.82%
Operating Income Growth %	-0.79%	0.29%	0.51%	0.36%	-0.06%	-0.13%	-0.09%	0.15%	0.13%	-1.84%
EBITDA+	-3.6M	-2.56M	-1.25M	-792K	0	-947K	-1.03M	-879K	-764K	-1.97M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-4.37%
EBITDA Growth %	-0.83%	0.29%	0.51%	0.36%	1%	-	-0.09%	0.15%	0.13%	-1.58%
D&A (Non-Cash Add-back)	7K	3K	1K	1K	842K	1K	1K	1K	1K	199K
EBIT	-2.01M	-1.71M	-1.25M	-793K	-842K	-948K	-1.03M	-880K	-765K	-1.13M
Net Interest Income+	0	0	8K	80K	64K	16K	-13K	25K	37K	-52K
Interest Income	0	0	16K	87K	93K	33K	8K	36K	41K	34K
Interest Expense	0	0	8K	7K	29K	17K	21K	11K	4K	86K
Other Income/Expense	-11K	16K	465K	4.42M	79K	-2.01M	1.47M	-468K	-1.02M	1.01M
Pretax Income+	-3.62M	-2.54M	-781K	2.99M	-1.35M	-2.95M	435K	-1.35M	-1.78M	-1.16M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-2.57%
Income Tax+	0	0	0	-80K	-69K	0	0	0	0	-130K
Effective Tax Rate %	1.19%	1%	1%	1%	1%	0.26%	1%	1%	0%	0.89%
Net Income+	-4.31M	-2.54M	-781K	2.99M	-1.35M	-782K	435K	-1.35M	-1.78K	-1.03M
Net Margin %	-	-	-	-	-	-	-	-	-	-2.28%
Net Income Growth %	-0.71%	0.41%	0.69%	4.82%	-1.45%	0.42%	1.56%	-4.1%	1%	-575.32%
Net Income (Continuing)	-3.62M	-2.54M	-781K	3.63M	-763K	-2.95M	435K	-1.35M	-1.78M	-1.03M
Discontinued Operations	-691K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.52	-3.72	-0.68	2.32	-1.04	-2.28	0.28	-1.00	0.00	-0.60
EPS Growth %	-0.5%	0.43%	0.82%	4.41%	-1.45%	-1.19%	1.12%	-4.57%	1%	-
EPS (Basic)	-6.52	-3.72	-0.68	2.32	-1.04	-2.28	0.32	-1.00	0.00	-0.60
Diluted Shares Outstanding	659.33K	685.09K	1.18M	1.29M	1.29M	1.29M	1.54M	1.36M	1.36M	1.76M
Basic Shares Outstanding	659.33K	685.09K	1.18M	1.29M	1.29M	1.29M	1.33M	1.36M	1.36M	1.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.26M	2.75M	6.21M	8.2M	6.83M	6.12M	6.24M	3.81M	2.05M	1.34M
Cash & Short-Term Investments	4.07M	2.43M	6.09M	8.12M	6.73M	6.04M	6.13M	3.72M	2.01M	1.14M
Cash Only	3.82M	2.02M	3.29M	3.25M	4.46M	3.63M	2.97M	2.09M	1.4M	371K
Short-Term Investments	251K	414K	2.81M	4.87M	2.27M	2.41M	3.16M	1.63M	605K	772K
Accounts Receivable	0	12K	0	0	0	0	94K	71K	29K	99K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	80.12
Inventory	0	130K	85K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	137K	179K	0	0	20K	13K	-78K	-57K	-18K	47K
Total Non-Current Assets+	1.06M	263K	380K	380K	382K	382K	381K	380K	380K	7.21M
Property, Plant & Equipment	11K	10K	0	0	2K	2K	1K	0	0	187K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	2.41x
Goodwill	0	0	0	0	0	0	0	0	0	3.19M
Intangible Assets	1.04M	253K	380K	380K	380K	380K	380K	380K	380K	3.82M
Long-Term Investments	0	0	0	0	0	0	0	0	0	14K
Other Non-Current Assets	10K	0	0	0	0	0	0	0	0	0
Total Assets+	5.32M	3.02M	6.59M	8.57M	7.21M	6.5M	6.62M	4.19M	2.43M	8.55M
Asset Turnover	-	-	-	-	-	-	-	-	-	0.05x
Asset Growth %	-0.06%	-0.43%	1.18%	0.3%	-0.16%	-0.1%	0.02%	-0.37%	-0.42%	2.52%
Total Current Liabilities+	436K	330K	300K	253K	232K	254K	231K	187K	206K	2.21M
Accounts Payable	118K	17K	4K	253K	1K	2K	2K	2K	1K	196K
Days Payables Outstanding	-	-	-	-	-	730	730	730	-	159.69
Short-Term Debt	0	0	0	0	0	0	0	0	0	138K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	18K
Other Current Liabilities	0	0	0	0	0	0	0	0	0	1.33M
Current Ratio	9.78x	8.35x	20.69x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Quick Ratio	9.78x	7.95x	20.40x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	2.67M	0	465K	2.64M	1.05M	0	0	908K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	219K
Other Non-Current Liabilities	0	0	2.67M	0	465K	2.64M	1.05M	0	0	689K
Total Liabilities	436K	330K	2.97M	253K	232K	254K	1.28M	187K	206K	3.12M
Total Debt+	0	0	0	0	0	0	0	0	0	138K
Net Debt	-3.82M	-2.02M	-3.29M	-3.25M	-4.46M	-3.63M	-2.97M	-2.09M	-1.4M	-233K
Debt / Equity	-	-	-	-	-	-	-	-	-	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-25.26x
Total Equity+	4.89M	2.69M	3.62M	8.32M	6.98M	6.25M	5.33M	4M	2.22M	5.43M
Equity Growth %	0.04%	-0.45%	0.35%	1.3%	-0.16%	-0.1%	-0.15%	-0.25%	-0.44%	1.45%
Book Value per Share	7.41	3.92	3.08	6.47	5.43	4.86	3.47	2.94	1.63	3.09
Total Shareholders' Equity	4.89M	2.69M	3.62M	8.32M	6.98M	3.61M	5.33M	4M	2.22M	5.43M
Common Stock	6.61M	6.62M	13.18M	13.18M	13.18M	13.18M	14.12M	14.12M	14.12M	23.14M
Retained Earnings	-152.49M	-154.9M	-155.65M	-152.59M	-153.93M	-155.6M	-155.13M	-156.47M	-158.25M	-159.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	20K	183K	67K	20K	20K	20K	20K	20K	20K	20K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.86M	-1.73M	-1.13M	-816K	-908K	-850K	-1.05M	-901K	-707K	-1.62M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-3.59%
Operating CF Growth %	0.25%	0.07%	0.35%	0.27%	-0.11%	0.06%	-0.23%	0.14%	0.22%	-1.29%
Net Income	-4.31M	-2.54M	-781K	2.99M	-1.35M	-2.95M	435K	-1.35M	-1.78M	-1.03M
Depreciation & Amortization	7K	3K	1K	0	0	1K	1K	1K	0	199K
Stock-Based Compensation	148K	182K	40K	24K	5K	51K	37K	14K	3K	264K
Deferred Taxes	2.31M	-182K	-755K	0	0	0	0	487K	0	-130K
Other Non-Cash Items	2.31M	848K	-437K	-3.82M	484K	2.01M	-1.47M	-36K	1.01M	-1.11M
Working Capital Changes	-16K	-220K	52K	-8K	-50K	45K	-54K	-19K	64K	189K
Change in Receivables	36	-114	0	0	0	0	0	0	0	39K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-117K	-101K	-13K	-47K	-21K	22K	-23K	-44K	19K	208K
Cash from Investing+	-110K	-66K	-2.5M	778K	2.11M	32K	8K	36K	41K	-844K
Capital Expenditures	-66K	-66K	0	0	-2K	-1K	0	0	0	-54K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	0.12%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-43K	-64K	5K	74K	93K	33K	8K	36K	41K	-366K
Cash from Financing+	3.58M	0	4.89M	0	0	0	385K	0	0	1.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	20K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.93M	-1.8M	-1.13M	-816K	-910K	-851K	-1.05M	-901K	-707K	-1.67M
FCF Margin %	-	-	-	-	-	-	-	-	-	-3.71%
FCF Growth %	0.22%	0.07%	0.37%	0.27%	-0.12%	0.06%	-0.23%	0.14%	0.22%	-1.36%
FCF per Share	-2.92	-2.62	-0.96	-0.63	-0.71	-0.66	-0.68	-0.66	-0.52	-0.95
FCF Conversion (FCF/Net Income)	0.43x	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-90.13%	-67.2%	-24.77%	50.01%	-17.61%	-11.82%	7.51%	-28.89%	-0.06%	-26.83%
Return on Invested Capital (ROIC)	-150.88%	-221.03%	-187.27%	-22.04%	-16.64%	-27.65%	-31.04%	-30.92%	-42.13%	-54.11%
Gross Margin	-	-	-	-	-	-	-	-	-	0.67%
Net Margin	-	-	-	-	-	-	-	-	-	-227.72%
Debt / Equity	-	-	-	-	-	-	-	-	-	0.03x
Interest Coverage	-	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-25.26x
FCF Conversion	0.43x	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x

Frequently Asked Questions

Growth & Financials

XTL Biopharmaceuticals Ltd. (XTLB) reported $0.5M in revenue for fiscal year 2024.

XTL Biopharmaceuticals Ltd. (XTLB) grew revenue by 0.0% over the past year. Growth has been modest.

XTL Biopharmaceuticals Ltd. (XTLB) reported a net loss of $1.0M for fiscal year 2024.

Dividend & Returns

XTL Biopharmaceuticals Ltd. (XTLB) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.

XTL Biopharmaceuticals Ltd. (XTLB) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

XTL Biopharmaceuticals Ltd. (XTLB) 10-Year Financial Performance & Capital Metrics

XTLB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $451K
EBITDA -$2M -158.2%
Net Income -$1M -57531.9%
EPS (Diluted) -0.60
Gross Margin 0.67%
EBITDA Margin -437.47%
Operating Margin -481.6%
Net Margin -227.72%
ROE -26.83% -46727.4%
ROIC -54.11% -28.5%
Debt/Equity 0.03
Interest Coverage -25.26 +86.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 29.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM42.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM45.45%

ROCE

10Y Avg-31.57%

5Y Avg-24.59%

3Y Avg-30.76%

Latest-50.73%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	451K
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	1K	1K	1K	0	448K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.99%
Gross Profit+	0	0	0	0	0	-1K	-1K	-1K	0	3K
Gross Margin %	-	-	-	-	-	-	-	-	-	0.01%
Gross Profit Growth %	1%	-	-	-	-	-	0%	0%	1%	-
Operating Expenses+	2M	1.71M	1.25M	793K	842K	948K	1.03M	880K	765K	2.17M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	4.82%
Selling, General & Admin	1.41M	1.26M	1.19M	755K	807K	910K	1M	850K	734K	2.05M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	4.54%
Research & Development	578K	443K	43K	38K	35K	38K	30K	30K	31K	98K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	0.22%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	31K
Operating Income+	-3.61M	-2.56M	-1.25M	-793K	-842K	-948K	-1.03M	-880K	-765K	-2.17M
Operating Margin %	-	-	-	-	-	-	-	-	-	-4.82%
Operating Income Growth %	-0.79%	0.29%	0.51%	0.36%	-0.06%	-0.13%	-0.09%	0.15%	0.13%	-1.84%
EBITDA+	-3.6M	-2.56M	-1.25M	-792K	0	-947K	-1.03M	-879K	-764K	-1.97M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-4.37%
EBITDA Growth %	-0.83%	0.29%	0.51%	0.36%	1%	-	-0.09%	0.15%	0.13%	-1.58%
D&A (Non-Cash Add-back)	7K	3K	1K	1K	842K	1K	1K	1K	1K	199K
EBIT	-2.01M	-1.71M	-1.25M	-793K	-842K	-948K	-1.03M	-880K	-765K	-1.13M
Net Interest Income+	0	0	8K	80K	64K	16K	-13K	25K	37K	-52K
Interest Income	0	0	16K	87K	93K	33K	8K	36K	41K	34K
Interest Expense	0	0	8K	7K	29K	17K	21K	11K	4K	86K
Other Income/Expense	-11K	16K	465K	4.42M	79K	-2.01M	1.47M	-468K	-1.02M	1.01M
Pretax Income+	-3.62M	-2.54M	-781K	2.99M	-1.35M	-2.95M	435K	-1.35M	-1.78M	-1.16M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-2.57%
Income Tax+	0	0	0	-80K	-69K	0	0	0	0	-130K
Effective Tax Rate %	1.19%	1%	1%	1%	1%	0.26%	1%	1%	0%	0.89%
Net Income+	-4.31M	-2.54M	-781K	2.99M	-1.35M	-782K	435K	-1.35M	-1.78K	-1.03M
Net Margin %	-	-	-	-	-	-	-	-	-	-2.28%
Net Income Growth %	-0.71%	0.41%	0.69%	4.82%	-1.45%	0.42%	1.56%	-4.1%	1%	-575.32%
Net Income (Continuing)	-3.62M	-2.54M	-781K	3.63M	-763K	-2.95M	435K	-1.35M	-1.78M	-1.03M
Discontinued Operations	-691K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.52	-3.72	-0.68	2.32	-1.04	-2.28	0.28	-1.00	0.00	-0.60
EPS Growth %	-0.5%	0.43%	0.82%	4.41%	-1.45%	-1.19%	1.12%	-4.57%	1%	-
EPS (Basic)	-6.52	-3.72	-0.68	2.32	-1.04	-2.28	0.32	-1.00	0.00	-0.60
Diluted Shares Outstanding	659.33K	685.09K	1.18M	1.29M	1.29M	1.29M	1.54M	1.36M	1.36M	1.76M
Basic Shares Outstanding	659.33K	685.09K	1.18M	1.29M	1.29M	1.29M	1.33M	1.36M	1.36M	1.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.26M	2.75M	6.21M	8.2M	6.83M	6.12M	6.24M	3.81M	2.05M	1.34M
Cash & Short-Term Investments	4.07M	2.43M	6.09M	8.12M	6.73M	6.04M	6.13M	3.72M	2.01M	1.14M
Cash Only	3.82M	2.02M	3.29M	3.25M	4.46M	3.63M	2.97M	2.09M	1.4M	371K
Short-Term Investments	251K	414K	2.81M	4.87M	2.27M	2.41M	3.16M	1.63M	605K	772K
Accounts Receivable	0	12K	0	0	0	0	94K	71K	29K	99K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	80.12
Inventory	0	130K	85K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	137K	179K	0	0	20K	13K	-78K	-57K	-18K	47K
Total Non-Current Assets+	1.06M	263K	380K	380K	382K	382K	381K	380K	380K	7.21M
Property, Plant & Equipment	11K	10K	0	0	2K	2K	1K	0	0	187K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	2.41x
Goodwill	0	0	0	0	0	0	0	0	0	3.19M
Intangible Assets	1.04M	253K	380K	380K	380K	380K	380K	380K	380K	3.82M
Long-Term Investments	0	0	0	0	0	0	0	0	0	14K
Other Non-Current Assets	10K	0	0	0	0	0	0	0	0	0
Total Assets+	5.32M	3.02M	6.59M	8.57M	7.21M	6.5M	6.62M	4.19M	2.43M	8.55M
Asset Turnover	-	-	-	-	-	-	-	-	-	0.05x
Asset Growth %	-0.06%	-0.43%	1.18%	0.3%	-0.16%	-0.1%	0.02%	-0.37%	-0.42%	2.52%
Total Current Liabilities+	436K	330K	300K	253K	232K	254K	231K	187K	206K	2.21M
Accounts Payable	118K	17K	4K	253K	1K	2K	2K	2K	1K	196K
Days Payables Outstanding	-	-	-	-	-	730	730	730	-	159.69
Short-Term Debt	0	0	0	0	0	0	0	0	0	138K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	18K
Other Current Liabilities	0	0	0	0	0	0	0	0	0	1.33M
Current Ratio	9.78x	8.35x	20.69x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Quick Ratio	9.78x	7.95x	20.40x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	2.67M	0	465K	2.64M	1.05M	0	0	908K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	219K
Other Non-Current Liabilities	0	0	2.67M	0	465K	2.64M	1.05M	0	0	689K
Total Liabilities	436K	330K	2.97M	253K	232K	254K	1.28M	187K	206K	3.12M
Total Debt+	0	0	0	0	0	0	0	0	0	138K
Net Debt	-3.82M	-2.02M	-3.29M	-3.25M	-4.46M	-3.63M	-2.97M	-2.09M	-1.4M	-233K
Debt / Equity	-	-	-	-	-	-	-	-	-	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-25.26x
Total Equity+	4.89M	2.69M	3.62M	8.32M	6.98M	6.25M	5.33M	4M	2.22M	5.43M
Equity Growth %	0.04%	-0.45%	0.35%	1.3%	-0.16%	-0.1%	-0.15%	-0.25%	-0.44%	1.45%
Book Value per Share	7.41	3.92	3.08	6.47	5.43	4.86	3.47	2.94	1.63	3.09
Total Shareholders' Equity	4.89M	2.69M	3.62M	8.32M	6.98M	3.61M	5.33M	4M	2.22M	5.43M
Common Stock	6.61M	6.62M	13.18M	13.18M	13.18M	13.18M	14.12M	14.12M	14.12M	23.14M
Retained Earnings	-152.49M	-154.9M	-155.65M	-152.59M	-153.93M	-155.6M	-155.13M	-156.47M	-158.25M	-159.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	20K	183K	67K	20K	20K	20K	20K	20K	20K	20K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.86M	-1.73M	-1.13M	-816K	-908K	-850K	-1.05M	-901K	-707K	-1.62M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-3.59%
Operating CF Growth %	0.25%	0.07%	0.35%	0.27%	-0.11%	0.06%	-0.23%	0.14%	0.22%	-1.29%
Net Income	-4.31M	-2.54M	-781K	2.99M	-1.35M	-2.95M	435K	-1.35M	-1.78M	-1.03M
Depreciation & Amortization	7K	3K	1K	0	0	1K	1K	1K	0	199K
Stock-Based Compensation	148K	182K	40K	24K	5K	51K	37K	14K	3K	264K
Deferred Taxes	2.31M	-182K	-755K	0	0	0	0	487K	0	-130K
Other Non-Cash Items	2.31M	848K	-437K	-3.82M	484K	2.01M	-1.47M	-36K	1.01M	-1.11M
Working Capital Changes	-16K	-220K	52K	-8K	-50K	45K	-54K	-19K	64K	189K
Change in Receivables	36	-114	0	0	0	0	0	0	0	39K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-117K	-101K	-13K	-47K	-21K	22K	-23K	-44K	19K	208K
Cash from Investing+	-110K	-66K	-2.5M	778K	2.11M	32K	8K	36K	41K	-844K
Capital Expenditures	-66K	-66K	0	0	-2K	-1K	0	0	0	-54K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	0.12%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-43K	-64K	5K	74K	93K	33K	8K	36K	41K	-366K
Cash from Financing+	3.58M	0	4.89M	0	0	0	385K	0	0	1.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	20K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.93M	-1.8M	-1.13M	-816K	-910K	-851K	-1.05M	-901K	-707K	-1.67M
FCF Margin %	-	-	-	-	-	-	-	-	-	-3.71%
FCF Growth %	0.22%	0.07%	0.37%	0.27%	-0.12%	0.06%	-0.23%	0.14%	0.22%	-1.36%
FCF per Share	-2.92	-2.62	-0.96	-0.63	-0.71	-0.66	-0.68	-0.66	-0.52	-0.95
FCF Conversion (FCF/Net Income)	0.43x	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-90.13%	-67.2%	-24.77%	50.01%	-17.61%	-11.82%	7.51%	-28.89%	-0.06%	-26.83%
Return on Invested Capital (ROIC)	-150.88%	-221.03%	-187.27%	-22.04%	-16.64%	-27.65%	-31.04%	-30.92%	-42.13%	-54.11%
Gross Margin	-	-	-	-	-	-	-	-	-	0.67%
Net Margin	-	-	-	-	-	-	-	-	-	-227.72%
Debt / Equity	-	-	-	-	-	-	-	-	-	0.03x
Interest Coverage	-	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-25.26x
FCF Conversion	0.43x	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x

Frequently Asked Questions

Growth & Financials

XTL Biopharmaceuticals Ltd. (XTLB) reported $0.5M in revenue for fiscal year 2024.

XTL Biopharmaceuticals Ltd. (XTLB) grew revenue by 0.0% over the past year. Growth has been modest.

XTL Biopharmaceuticals Ltd. (XTLB) reported a net loss of $1.0M for fiscal year 2024.

Dividend & Returns

XTL Biopharmaceuticals Ltd. (XTLB) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.

XTL Biopharmaceuticals Ltd. (XTLB) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.